News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
475,251 Results
Type
Article (23688)
Company Profile (164)
Press Release (451399)
Section
Business (147073)
Career Advice (1520)
Deals (27314)
Drug Delivery (91)
Drug Development (58813)
Employer Resources (142)
FDA (10971)
Job Trends (11134)
News (249844)
Policy (22925)
Tag
Academia (1324)
Alliances (37223)
Alzheimer's disease (854)
Approvals (10966)
Artificial intelligence (133)
Bankruptcy (239)
Best Places to Work (8503)
Biotechnology (88)
Breast cancer (122)
Cancer (990)
Career advice (1280)
Cell therapy (214)
Clinical research (48167)
Collaboration (370)
Compensation (136)
COVID-19 (1410)
C-suite (95)
Data (1074)
Diabetes (126)
Diagnostics (4134)
Drug pricing (91)
Earnings (55139)
Employer resources (120)
Events (69885)
Executive appointments (347)
FDA (11492)
Funding (307)
Gene therapy (151)
GLP-1 (436)
Government (2714)
Healthcare (11131)
Infectious disease (1466)
Inflammatory bowel disease (83)
Interviews (239)
IPO (11967)
Job creations (2966)
Job search strategy (1115)
Layoffs (243)
Legal (5096)
Lung cancer (137)
Lymphoma (78)
Manufacturing (187)
Medical device (7950)
Medtech (7954)
Mergers & acquisitions (15546)
Metabolic disorders (334)
Neuroscience (1078)
NextGen Class of 2024 (4274)
Non-profit (1979)
Northern California (1206)
Obesity (187)
Opinion (209)
Patents (106)
People (45672)
Phase I (14597)
Phase II (21229)
Phase III (16416)
Pipeline (425)
Policy (84)
Postmarket research (1706)
Preclinical (5762)
Radiopharmaceuticals (197)
Rare diseases (200)
Real estate (4410)
Regulatory (16156)
Research institute (1347)
Resumes & cover letters (243)
Southern California (1071)
Startups (2596)
United States (11041)
Vaccines (250)
Weight loss (136)
Date
Today (16)
Last 7 days (59)
Last 30 days (1564)
Last 365 days (26303)
2024 (26303)
2023 (29981)
2022 (39077)
2021 (41191)
2020 (39393)
2019 (32674)
2018 (24566)
2017 (24092)
2016 (22473)
2015 (26412)
2014 (20098)
2013 (16752)
2012 (18249)
2011 (18987)
2010 (17067)
Location
Africa (563)
Arizona (95)
Asia (32200)
Australia (6094)
California (2715)
Canada (1170)
China (260)
Colorado (128)
Connecticut (146)
Europe (63411)
Florida (377)
Illinois (291)
Indiana (159)
Japan (78)
Maryland (411)
Massachusetts (2126)
Michigan (129)
Minnesota (155)
New Jersey (917)
New York (832)
North Carolina (583)
Northern California (1206)
Ohio (110)
Pennsylvania (691)
South America (893)
Southern California (1071)
Texas (402)
Washington State (310)
475,251 Results for "teva pharmaceutical industries limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Teva Reports Strong Generics Demand in Q3, Expects Higher 2024 Revenue
Driven by copycat versions of Bristol Myers Squibb’s Revlimid and Novo Nordisk’s Victoza, Teva’s generics business was again a top-performer in the third quarter, with U.S. sales growing 30% and bringing in $1.1 billion in sales.
November 7, 2024
·
2 min read
·
Tristan Manalac
Pharm Country
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States
Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of an authorized generic of Victoza®1 (liraglutide injection 1.8mg), in the United States.
June 24, 2024
·
9 min read
Legal
Teva to Pay $450M in Settlement With DOJ Over Kickback and Price-Fixing Allegations
The U.S. Department of Justice alleged that Teva violated the Anti-Kickback Statute and the False Claims Act. The payment is in addition to the criminal penalty paid by Teva USA under its deferred prosecution agreement.
October 11, 2024
·
2 min read
·
Tristan Manalac
Business
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
Teva Pharmaceutical Industries Ltd. today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company’s manufacturing and supply division, effective June 3, 2024.
May 15, 2024
·
7 min read
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva’s President and CEO, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024.
June 4, 2024
·
2 min read
Policy
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
UroGen Pharma Ltd. today announced that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries, Ltd., alleging infringement of U.S. Patent Numbers 9,040,074 (“the ’074 patent”) and 9,950,069.
April 3, 2024
·
9 min read
Teva to Present at the 2024 Bank of America Healthcare Conference
Teva Pharmaceutical Industries Ltd. announced that Richard Francis, Teva’s President and CEO, will present at the 2024 Bank of America Healthcare Conference on Tuesday, May 14, 2024.
May 2, 2024
·
2 min read
Press Releases
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
December 6, 2024
·
4 min read
Business
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
Teva Pharmaceutical Industries Ltd. reported results for the quarter ended March 31, 2024.
May 8, 2024
·
52 min read
Pharm Country
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, reinforcing that TD has a wide-reaching, multidimensional impact on patients’ quality of life.
June 1, 2024
·
12 min read
1 of 47,526
Next
